Deepthi Bhupathi
Fluxion Biosciences (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Epigenetics and DNA Methylation, Cancer-related Molecular Pathways, RNA modifications and cancer, Cancer Research and Treatments
Most-Cited Works
- → Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302(2011)205 cited
- → Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer(2015)51 cited
- Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.(2015)
- → Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition(2015)24 cited
- → 14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment(2011)21 cited
- → Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models(2018)18 cited
- → Abstract 6093: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors(2023)14 cited
- → Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity(2022)12 cited
- → Deletion mutational analysis of BMRP, a pro-apoptotic protein that binds to Bcl-2(2011)9 cited
- → 705 Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)(2020)8 cited